Bcal Diagnostics Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.00%

Bcal Diagnostics Ltd (BDX) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BDX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

AU$8.37 Million

≈ $5.92 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2022)

This chart shows how Bcal Diagnostics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Bcal Diagnostics Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Bcal Diagnostics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Bcal Diagnostics Ltd for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Bcal Diagnostics Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Bcal Diagnostics Ltd Industry Peers by Asset Resilience Ratio

Compare Bcal Diagnostics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
GeneDx Holdings Corp. NASDAQ:WGS	Diagnostics & Research	15.00%
Shanghai Runda Med Tech Co SHG:603108	Diagnostics & Research	0.42%
Shanghai Rendu Biotechnology Co. Ltd. A SHG:688193	Diagnostics & Research	70.50%
DIVA Laboratories Ltd TWO:4153	Diagnostics & Research	0.01%
Genoray Co. Ltd KQ:122310	Diagnostics & Research	2.14%
RHYTHM Biosciences Ltd AU:RHY	Diagnostics & Research	2.74%
Check-Cap Ltd F:7CC	Diagnostics & Research	2.90%
Avricore Health Inc V:AVCR	Diagnostics & Research	1.71%

Annual Asset Resilience Ratio for Bcal Diagnostics Ltd (2021–2022)

The table below shows the annual Asset Resilience Ratio data for Bcal Diagnostics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.00%	AU$0.00 ≈ $0.00	AU$8.37 Million ≈ $5.92 Million	--
2021-12-31	37.77%	AU$4.00 Million ≈ $2.83 Million	AU$10.59 Million ≈ $7.49 Million	--

pp = percentage points

About Bcal Diagnostics Ltd

AU:BDX Australia Diagnostics & Research

Market Cap

$18.26 Million

AU$25.81 Million AUD

Market Cap Rank

#25490 Global

#1095 in Australia

Share Price

AU$0.07

Change (1 day)

-1.41%

52-Week Range

AU$0.05 - AU$0.14

All Time High

AU$0.25